| Formulary Chapter 2: Cardiovascular system - Full Chapter
|
| Chapter Links... |
 Academic Health Science Network (North East and North Cumbria) - Atrial Fibrilation |
| County Durham and Darlington DVT Pathway Information |
| NICE NG148: Acute kidney injury: prevention, detection and management |
| NICE NG191: COVID-19 rapid guideline: managing COVID-19 |
| South Tees Hospitals Cardiology drug prescribing guidelines & formulary |
| Details... |
| 02.12 |
Lipid-regulating drugs |
|
|
Alirocumab
|
Formulary
|
- Only approved for use in accordance with NICE guidance.
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
|
Evolocumab
|
Formulary
|
- Approved for use in accordance with NICE guidance for treating primary hypercholesterolaemia.
- Approved for the treatment of homozygous familial hypercholesterolaemia in line with NHS England Commissioning policy.
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
|
Icosapent ethyl (Vazkepa®)
|
Formulary
|
- 998mg capsules
- Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have:
- established cardiovascular disease (secondary prevention), defined as a history of any of the following:
- acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
- coronary or other arterial revascularisation procedures
- coronary heart disease
- ischaemic stroke
- peripheral arterial disease, and
- low-density lipoprotein cholesterol (LDL‑C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre
|
NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
|
Inclisiran (Leqvio®)
|
Formulary
|
- 284mg/1.5ml solution for injection pre-filled syringes
- Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults in line with NICE.
|
NICE TA 733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
|
|
|
|
|
|
|
|
|
| 02.12 |
Bile acid sequestrants |
|
|
Colestyramine
|
Formulary
|
- For initiation in lipid clinic only in patients with familial hypercholesterolaemia and/or those with substantial cardiovascular risk and who are unable to tolerate existing treatments.
- Also approved for the treatment of leflunomide toxicity .
|
|
|
Colesevelam
|
Formulary
|
- For initiation in lipid clinic only in patients with familial hypercholesterolaemia and/or those with substantial cardiovascular risk and who are unable to tolerate existing treatments.
|
|
|
| 02.12 |
Ezetimibe |
|
|
Bempedoic acid (Nilemdo®)
|
Formulary
|
- 180mg tablets
- Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults in line with NICE and following the statin intensification pathway outlined in NEELI
|
NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
|
Bempedoic acid with ezetimibe (Nustendi®)
|
Formulary
|
- Bempedoic acid 180mg & ezetimibe 10mg tablets
- Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults in line with NICE and following the statin intensification pathway outlined in NEELI
|
NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
|
Ezetimibe
|
Formulary
|
- Only approved for use in accordance with NICE guidance.
- For further information refer to NEELI.
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
|
| 02.12 |
Fibrates |
|
|
 |
For initiation in lipid clinic only in patients with familial hypercholesterolaemia and/or those with substantial cardiovascular risk and who are unable to tolerate existing treatments. |
|
Fenofibrate
|
First Choice
|
For initiation in lipid clinic only in patients with combined hyperlipidaemias and severe hypertriglycerideamia.
|
MHRA Drug Safety Update (Dec 2010): Fibrates: first-line treatment not recommended
|
Bezafibrate
|
Formulary
|
|
MHRA Drug Safety Update (Dec 2010): Fibrates: first-line treatment not recommended
|
| 02.12 |
Statins |
|
|
|
Atorvastatin
|
First Choice
|
- 10mg, 20mg, 40mg & 80mg tablets
|
|
|
Rosuvastatin
|
Formulary
|
- 5mg, 10mg, 20mg & 40mg tablets
- May be used as an alternative to atorvastatin for primary or secondary prevention in line with NEELI guidance
|
|
|
Simvastatin
|
Alternatives
|
- 10mg, 20mg. 40mg & 80mg tablets
|
MHRA Drug Safety Update (Dec 2014): Simvastatin: dose limitations with concomitant amlodipine or diltiazem
|
Atorvastatin Chewable
|
Alternatives
|
- 10mg and 20mg chewable tablets
- Note: atorvastatin 10mg and 20mg chewable tablets should be used instead of simvastatin suspension where solid dosage forms cannot be used.
|
|
|
Pravastatin
|
Alternatives
|
- 10mg, 20mg & 40mg tablets
|
|
|
| 02.12 |
Nicotinic acid group |
|
|
| 02.12 |
Omega-3 fatty acid compounds |
|
|
| 02.12 |
PCSK9 inhibitors |
|
|
| 02.12 |
Other lipid modifying agents |
|
|
Evinacumab (Evkeeza®)
|
Formulary
|
|
NICE TA1002 : Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over
|
| .... |
| Non Formulary Items |
Omega-3 Fatty Acid Compounds (excluding icosapent ethyl [Vazkepa®])
|
Non Formulary
|
- Omega-3 fatty acid compounds are classified as BLACK - not approved.
|
|
|
| |
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment. In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances. For all RED drugs automatically added to the formulary in response to a positive NICE TA: Prescribers need to ensure that local Trust new drug governance procedures and pharmacy processes are followed before any prescribing. |
|
Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement. These medicines are considered suitable for primary care prescribing following specialist initiation of therapy and stabilisation, with ongoing communication between the primary care prescriber and specialist as set out in the associated shared care guideline (SCG). Shared care should be initiated by the specialist, which includes consultant, suitably trained specialist non-medical prescriber or GPwER within a secondary, tertiary, or primary care clinic.
The specialist should send the primary care prescriber a copy of the NENC Clinical Effectiveness and Governance (CEG) Subcommittee approved SCG to sign. The primary care prescriber should sign the SCG or indicate reasons why they are unable to accept the agreement and return a copy back to the specialist, as soon as possible.
SCGs are available or are being developed for most of the drugs listed as AMBER. |
|
Drugs normally recommended or initiated by a hospital specialist who is a prescriber, a GP with an extended role [GPwER], or a specialist within primary care which can be safely maintained in primary care and monitored in primary care. In some cases, a further restriction for use may be defined. The primary care prescriber must be familiar with the drug to take on prescribing responsibility or must obtain the required information from the specialist. Therefore, provision of additional information, or an information leaflet, may be appropriate in some cases to facilitate continuing treatment by primary care prescriber or provide information re stopping criteria.
These are considered suitable for primary care prescribing following specialist assessment and recommendation of therapy, with ongoing communication between the primary care prescriber and specialist, if necessary.
In some case these drugs require specialist initiation and short to medium term monitoring of efficacy or toxicity until the patient’s dose is stable. Following specialist review the patient may be transferred to primary care for ongoing prescribing. Ongoing prescribing by primary care can include, if required, additional dose titrations and assessment of efficacy, with ongoing communication between the primary care prescriber and specialist, if necessary.
If the drug requires urgent initiation, it is expected that the specialist undertakes the initial prescribing responsibility for an appropriate period of time, usually a minimum of 28 days. A GREEN+ drug can only be recommended to primary care for initiation if does not need to be initiated within 28 days. |
|
Medicines suitable for initiation, ongoing prescribing and discontinuation in all care settings, subject to appropriate communication between those responsible. |
|
UNDER REVIEW: drugs whose current formulary status or RAG status is currently under review. |
|
Drugs that have been considered by the NENC Clinical Effectiveness and Governance (CEG) Subcommittee (or other approved body) and are not approved for prescribing within the North East and North Cumbria ICS. These may also include all medicines with a “not NHS” or “DLCV” classification in the BNF, those agents as included within the NICE “Do not do” list, and those agents included with the NHS England: Items which should not routinely be prescribed in primary care. |
|
|
|
